These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 39069074)

  • 21. Reciprocal feedback regulation of ST3GAL1 and GFRA1 signaling in breast cancer cells.
    Fan TC; Yeo HL; Hsu HM; Yu JC; Ho MY; Lin WD; Chang NC; Yu J; Yu AL
    Cancer Lett; 2018 Oct; 434():184-195. PubMed ID: 30040982
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Loss of Numb promotes hepatic progenitor expansion and intrahepatic cholangiocarcinoma by enhancing Notch signaling.
    Shu Y; Xu Q; Xu Y; Tao Q; Shao M; Cao X; Chen Y; Wu Z; Chen M; Zhou Y; Zhou P; Shi Y; Bu H
    Cell Death Dis; 2021 Oct; 12(11):966. PubMed ID: 34667161
    [TBL] [Abstract][Full Text] [Related]  

  • 23. LncRNA-CCAT1 Promotes Migration, Invasion, and EMT in Intrahepatic Cholangiocarcinoma Through Suppressing miR-152.
    Zhang S; Xiao J; Chai Y; Du YY; Liu Z; Huang K; Zhou X; Zhou W
    Dig Dis Sci; 2017 Nov; 62(11):3050-3058. PubMed ID: 28921383
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overexpression of TBX3 suppresses tumorigenesis in experimental and human cholangiocarcinoma.
    Deng S; Lu X; Wang X; Liang B; Xu H; Yang D; Cui G; Yonemura A; Paine H; Zhou Y; Zhang Y; Simile MM; Urigo F; Evert M; Calvisi DF; Green BL; Chen X
    Cell Death Dis; 2024 Jun; 15(6):441. PubMed ID: 38909034
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma.
    Di Matteo S; Nevi L; Costantini D; Overi D; Carpino G; Safarikia S; Giulitti F; Napoletano C; Manzi E; De Rose AM; Melandro F; Bragazzi M; Berloco PB; Giuliante F; Grazi G; Giorgi A; Cardinale V; Adorini L; Gaudio E; Alvaro D
    PLoS One; 2019; 14(1):e0210077. PubMed ID: 30677052
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD147 augmented monocarboxylate transporter-1/4 expression through modulation of the Akt-FoxO3-NF-κB pathway promotes cholangiocarcinoma migration and invasion.
    Dana P; Saisomboon S; Kariya R; Okada S; Obchoei S; Sawanyawisuth K; Wongkham C; Pairojkul C; Wongkham S; Vaeteewoottacharn K
    Cell Oncol (Dordr); 2020 Apr; 43(2):211-222. PubMed ID: 31729681
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Crenigacestat, a selective NOTCH1 inhibitor, reduces intrahepatic cholangiocarcinoma progression by blocking VEGFA/DLL4/MMP13 axis.
    Mancarella S; Serino G; Dituri F; Cigliano A; Ribback S; Wang J; Chen X; Calvisi DF; Giannelli G
    Cell Death Differ; 2020 Aug; 27(8):2330-2343. PubMed ID: 32042099
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High expression of protein tyrosine kinase 7 significantly associates with invasiveness and poor prognosis in intrahepatic cholangiocarcinoma.
    Jin J; Ryu HS; Lee KB; Jang JJ
    PLoS One; 2014; 9(2):e90247. PubMed ID: 24587299
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aldehyde dehydrogenase 3B2 promotes the proliferation and invasion of cholangiocarcinoma by increasing Integrin Beta 1 expression.
    Wang Y; Li K; Zhao W; Liu Z; Liu J; Shi A; Chen T; Mu W; Xu Y; Pan C; Zhang Z
    Cell Death Dis; 2021 Dec; 12(12):1158. PubMed ID: 34907179
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular profiling of intrahepatic cholangiocarcinoma: the search for new therapeutic targets.
    Oliveira DV; Zhang S; Chen X; Calvisi DF; Andersen JB
    Expert Rev Gastroenterol Hepatol; 2017 Apr; 11(4):349-356. PubMed ID: 28162004
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma.
    Dong L; Lu D; Chen R; Lin Y; Zhu H; Zhang Z; Cai S; Cui P; Song G; Rao D; Yi X; Wu Y; Song N; Liu F; Zou Y; Zhang S; Zhang X; Wang X; Qiu S; Zhou J; Wang S; Zhang X; Shi Y; Figeys D; Ding L; Wang P; Zhang B; Rodriguez H; Gao Q; Gao D; Zhou H; Fan J
    Cancer Cell; 2022 Jan; 40(1):70-87.e15. PubMed ID: 34971568
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Septin 9 expression regulates 'don't eat me' signals and identifies an immune-epithelial class of intrahepatic cholangiocarcinoma.
    Cai TT; Desterke C; Peng J; Agnetti J; Song P; Ouazib D; Dos Santos A; Guettier C; Samuel D; Gassama-Diagne A
    Mol Oncol; 2024 Oct; 18(10):2369-2392. PubMed ID: 39082897
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neurokinin-1 receptor antagonist aprepitant regulates autophagy and apoptosis via ROS/JNK in intrahepatic cholangiocarcinoma.
    Yang Y; Cao X; Wang Y; Wu X; Zhou P; Miao L; Deng X
    Liver Int; 2024 Jul; 44(7):1651-1667. PubMed ID: 38554043
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantitative Proteomics Reveals Down-Regulated Glycolysis/Gluconeogenesis in the Large-Duct Type Intrahepatic Cholangiocarcinoma.
    Guo Y; Li Q; Ren W; Wu H; Wang C; Li X; Xue B; Qiu Y; Zhang J; Chen J; Fang L
    J Proteome Res; 2022 Oct; 21(10):2504-2514. PubMed ID: 36066509
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of long non-coding RNA ANRIL predicts a poor prognosis in intrahepatic cholangiocarcinoma.
    Angenard G; Merdrignac A; Louis C; Edeline J; Coulouarn C
    Dig Liver Dis; 2019 Sep; 51(9):1337-1343. PubMed ID: 31040073
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HSF1 is a prognostic determinant and therapeutic target in intrahepatic cholangiocarcinoma.
    Cigliano A; Gigante I; Serra M; Vidili G; Simile MM; Steinmann S; Urigo F; Cossu E; Pes GM; Dore MP; Ribback S; Milia EP; Pizzuto E; Mancarella S; Che L; Pascale RM; Giannelli G; Evert M; Chen X; Calvisi DF
    J Exp Clin Cancer Res; 2024 Sep; 43(1):253. PubMed ID: 39243039
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Small duct and large duct type intrahepatic cholangiocarcinoma reveal distinct patterns of immune signatures.
    Bernatz S; Schulze F; Bein J; Bankov K; Mahmoudi S; Grünewald LD; Koch V; Stehle A; Schnitzbauer AA; Walter D; Finkelmeier F; Zeuzem S; Vogl TJ; Wild PJ; Kinzler MN
    J Cancer Res Clin Oncol; 2024 Jul; 150(7):357. PubMed ID: 39034327
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epigenetic dysregulation-mediated COL12A1 upregulation predicts worse outcome in intrahepatic cholangiocarcinoma patients.
    Tang Z; Yang Y; Zhang Q; Liang T
    Clin Epigenetics; 2023 Jan; 15(1):13. PubMed ID: 36694230
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CircZNF215 promotes tumor growth and metastasis through inactivation of the PTEN/AKT pathway in intrahepatic cholangiocarcinoma.
    Liao W; Du J; Li L; Wu X; Chen X; Feng Q; Xu L; Chen X; Liao M; Huang J; Yuan K; Zeng Y
    J Exp Clin Cancer Res; 2023 May; 42(1):125. PubMed ID: 37198696
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Utility of DNA flow cytometry in distinguishing between malignant and benign intrahepatic biliary lesions.
    Wen KW; Rabinovitch PS; Wang D; Mattis AN; Ferrell LD; Choi WT
    Virchows Arch; 2020 Oct; 477(4):527-534. PubMed ID: 32296928
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.